Blake E. Max
Clinical Associate Professor, Pharmacy Practice
Contact
Office Phone:
Email:
Related Sites:
About Heading link
Teaching and Supervision Heading link
Spec Project in Pharm Pract (PMPR 390), 1/9/2023 – 4/28/2023
Spec Project in Pharm Pract (PMPR 390), 1/10/2022 – 4/29/2022
Spec Project in Pharm Pract (PMPR 390), 1/11/2021 – 4/30/2021
Management of HIV Patient (PMPR 338), 9/2020 – 1/2021
Spec Project in Pharm Pract (PMPR 390), 1/13/2020 – 5/1/2020
Principles of Drug Action and Therapeutics (PHAR 506), 1/2020 – 5/2020
Co-Course Coordinator Inter-professional collaborative practice in HIV Care PMPR 390, Spring 2020 (PMPR 390), 1/2020 – 4/2020
PDAT 6: Infectious Diseases (PHAR 506), 1/14/2019 – 5/3/2019
Spec Project in Pharm Pract (PMPR 390), 1/14/2019 – 5/3/2019
Selected Grants
AIDS Education and Training Centers, US Department of Health & Human Services (Health Resources and Services Administration)., 9/1/2022 - 8/31/2027, Obligated Amount: $600000; Anticipated Amount: $3000000
Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV, National Cancer Institute., 2019 - 2025, Obligated Amount: $15000; No Anticipated Amount Set
Integrating the National HIV Curriculum e-Learning Platform into Health Care Provider Professional Education, US Department of Health & Human Services (Health Resources and Services Administration)., 9/1/2018 - 8/31/2022, Obligated Amount: $2287796; Anticipated Amount: $2400000
Selected Publications
Max, B, DeMarais, P. (2021). Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight. International Journal of STD and AIDS, 32, (1), 92-95. doi:10.1177/0956462420964341.
Rock, AE, DeMarais, PL, Vergara-Rodriguez, PT, Max, BE. (2020). HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir. Infectious Diseases and Therapy, 9, (3), 691-696. doi:10.1007/s40121-020-00307-4.
Max, Blake. (2020). I’m not that good with taking pills everyday. What Do I Do Now? – Infectious Diseases. Oxford University Press.
Max, B. (2019). Update on HIV integrase inhibitors for the treatment of HIV-1 infection. Future Virology, 14, (10), 693-709. doi:10.2217/fvl-2019-0077.
Max, Blake, Stevens, B. (2018). Test and Treat: A new model for better patient outcomes. HIV Specialist.
Huesgen, E, DeSear, KE, Egelund, EF, Smith, R, Max, B, Janelle, J. (2016). A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios. Pharmacotherapy, 36, (11), 1145-1165. doi:10.1002/phar.1835.
Max, B, Vibhakar, S. (2014). Dolutegravir: A new HIV integrase inhibitor for the treatment of HIV infection. Future Virology, 9, (11), 967-978. doi:10.2217/FVL.14.80.
Romo, Francine Touzard, Aziz, Mariam, Livak, Britt, Huesgen, Emily, Colton, Ben, Flanigan, Timothy P, Max, Blake, Kessler, Harold. (2014). Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment. Journal of AIDS & Clinical Research, 5, (11). doi:10.4172/2155-6113.1000379.
Huesgen, E, Burgos, R, Goldstein, DA, Max, B, Jarrett, OD. (2012). Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen. Antiviral Therapy, 17, (7), 1385-1388. doi:10.3851/IMP2182.
Professional Leadership
Medical Advisory Board, 2021 - Present
Exam review and question writing, 2021 - Present
American Academy of HIV Medicine (AAHIV) Credentialing Exam Writer, 1/2019 - Present
MATEC Pharmacy Coordinator for Continuing Education, 1/2005 - Present